KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.

Alan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, Eric L Simpson, Kim A Papp, Andrew Blauvelt, Chia-Yu Chu, H Chih-Ho Hong, Linda F Stein Gold, Marjolein de Bruin-Weller, Thomas Bieber, Kenji Kabashima, David Rosmarin, Cristina Sancho, Brian M Calimlim, Ayman Grada, Yang Yang, Xiaoqiang Wu, Gweneth Levy, Eliza M Raymundo, Henrique D Teixeira, Jonathan I Silverberg

Am J Clin Dermatol 26(6) 1003-1016

PMID40900410
PMCIDPMC12615543
DOI10.1007/s40257-025-00975-3
发表日期2025-09-03
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Upadacitinib is an oral selective Janus kinase inhibitor approved to treat moderate-to-severe atopic dermatitis (AD) in adults and adolescents; long-term efficacy and safety data beyond 1 year are needed. OBJECTIVE: The aim was to evaluate the long-term efficacy and safety of upadacitinib treatment through 140 weeks in patients with moderate-to-severe AD. METHODS: Measure Up 1 (MeUp1; NCT03569293), Measure Up 2 (MeUp2; NCT03607422), and AD Up (NCT03568318) are ongoing, phase 3, randomized clinical trials evaluating upadacitinib 15 mg (UPA15) and 30 mg (UPA30) in adults and adolescents with moderate-to-severe AD. This interim analysis evaluated efficacy and safety through week 140. At baseline, patients were randomized 1:1:1 to receive once-daily UPA15, UPA30, or placebo alone (MeUp1/2) or with concomitant topical corticosteroids (AD Up). At week 16, patients initially randomized to placebo were rerandomized 1:1 to UPA15 or UPA30. Skin and itch efficacy assessments included achievement of ≥ 75%/≥ 90%/100% improvement from baseline in Eczema Area and Severity Index (EASI 75/90/100), validated Investigator Global Assessment for AD score of clear/almost clear (vIGA-AD 0/1), and ≥ 4-point improvement from baseline in Worst Pruritus Numerical Rating Scale (∆WP-NRS≥4). Safety assessments included incidence of treatment-emergent adverse events. RESULTS: A total of 2782 patients were randomized in MeUp1/2 or AD Up. Efficacy response rates, including optimal outcomes such as EASI 90 and WP-NRS score of 0/1, were sustained through week 140 in all three studies. At week 140, EASI 75 was achieved by 85.5%/90.5% (UPA15/UPA30; integrated MeUp1/2) and 81.5%/90.0% (UPA15/UPA30; AD Up) of patients, and vIGA-AD 0/1 was achieved by 56.6%/64.4% (UPA15/UPA30; integrated MeUp1/2) and 52.0%/56.8% (UPA15/UPA30; AD Up) of patients. Over 60% of patients across all three studies achieved ∆WP-NRS≥4 at week 140. Pooled safety data across all three studies demonstrated safety profiles consistent with 16-week and 52-week analyses. CONCLUSIONS: UPA15 and UPA30 with and without topical corticosteroids demonstrated robust, durable efficacy and a favorable safety profile through 140 weeks in adults and adolescents with moderate-to-severe AD. TRIAL REGISTRATION: Measure Up 1 (NCT03569293; https://clinicaltrials.gov/study/NCT03569293 ), Measure Up 2 (NCT03607422; https://clinicaltrials.gov/study/NCT03607422 ), and AD Up (NCT03568318; https://clinicaltrials.gov/study/NCT03568318 ).

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 1

Fig. 1 Achievement of EASI 75, vIGA-AD 0/1, EASI 90, or EASI 100 through week 140 (Measure Up 1 and 2). The proportion of patients in Measure Up 1 and 2 (integrated data; OC analysis) who achieved a EASI 75, b vIGA-AD 0/1, c EASI 90, or d EASI 100. CI confidence interval, EASI 75/90/100 ≥ 75%/≥ 90%/100% improvement from baseline in Eczema Area and Severity Index, OC observed cases without imputation for missing data, UPA upadacitinib, vIGA-AD 0/1 clear (0) or almost clear (1) with ≥ 2 grades of improvement on the validated Investigator Global Assessment for Atopic Dermatitis

A

EASI 75

Fig. 1 · Panel A

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

vIGA-AD 0/1

Fig. 1 · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 1:off origin start曲线 2:off origin start曲线 3:off origin start
查看结果
C

EASI 90

Fig. 1 · Panel C

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

EASI 100

Fig. 1 · Panel D

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 3:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Fig. 2 Achievement of ΔWP-NRS≥4 and WP-NRS 0/1 through week 140 (Measure Up 1 and 2). The proportion of patients in Measure Up 1 and 2 (integrated data; OC analysis) who achieved a ΔWP-NRS≥4 or b WP-NRS 0/1. CI confidence interval, OC observed cases without imputation for missing data, UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale, WP-NRS 0/1 WP-NRS score of 0 or 1 (no/minimal itch) among patients with WP-NRS score > 1 at baseline, ΔWP-NRS≥4, ≥ 4-point improvement in WP-NRS among patients with WP-NRS score ≥ 4 at baseline
非 KM Figure
Fig. 3Fig. 3 Simultaneous achievement of EASI 90 and WP-NRS 0/1 through week 140 (Measure Up 1 and 2). The proportion of patients in Measure Up 1 and 2 (integrated data; OC analysis) who simultaneously achieved EASI 90 and WP-NRS 0/1. CI confidence interval, EASI 90 ≥ 90% improvement from baseline in Eczema Area and Severity Index, OC observed cases without imputation for missing data, UPA upadacitinib, WP-NRS Worst Pruritus Numerical Rating Scale, WP-NRS 0/1 WP-NRS score of 0 or 1 (no/minimal itch) among patients with WP-NRS score > 1 at baseline
非 KM Figure